Summary & Overview
HCPCS J1570: Injection, ganciclovir sodium 500 mg
HCPCS Level II code J1570 denotes a 500 mg injection of ganciclovir sodium, an intravenous antiviral used for systemic treatment of serious viral infections. This HCPCS code is relevant nationally for hospital and outpatient infusion billing and for payers that reimburse parenteral antiviral therapies. It matters because ganciclovir is a specialty injectable medication often administered in controlled clinical settings and can represent significant drug costs and utilization for payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J1570 represents clinically and operationally, followed by national benchmarking and payer coverage considerations where available. The publication outlines expected service lines and typical sites of service for administration, highlights common billing modifiers and payer interactions, and provides context useful for revenue cycle, clinical pharmacy, and utilization management teams.
The report offers: (1) a clinical and billing description of the service, (2) what payers commonly assess for injectable antivirals, and (3) practical coverage and coding considerations for infusion settings. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1570 represents an injection of ganciclovir sodium, 500 mg. The service is an intravenous antiviral injection typically administered for systemic treatment of viral infections where ganciclovir is indicated. Typical sites of service for this medication include hospital inpatient units, hospital outpatient infusion centers, and ambulatory infusion clinics where parenteral antiviral therapy is provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with proven or suspected cytomegalovirus (CMV) infection or disease requiring systemic antiviral therapy. Patients may present with CMV viremia after organ transplantation, CMV retinitis in immunocompromised individuals, or severe CMV disease (e.g., pneumonitis, colitis) in patients with neutropenia or advanced immunosuppression. The medication J1570 (injection, ganciclovir sodium, 500 mg) is administered intravenously by an infusion nurse or pharmacist in an outpatient infusion center, hospital inpatient unit, or skilled nursing facility.
Typical clinical workflow: prior to administration the clinician documents the indication and baseline labs (CBC with differential, renal function, and viral load), verifies dose based on weight and renal function, obtains informed consent, and prepares the IV infusion. A clinician or pharmacist reconstitutes the vial and delivers the ordered dose; an infusion nurse administers per facility protocol (often over 1 hour for induction dosing), monitors for adverse reactions (hematologic toxicity, renal toxicity), documents lot number and amount administered, and schedules follow-up laboratory monitoring and infectious disease or transplant clinic visits. For home health or outpatient infusion services, billing uses the J1570 HCPCS code per 500 mg unit administered, with appropriate modifiers appended as indicated by payer rules and clinical circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|